Matthew Techy, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Argenx US, Inc. at 29.8% of the total. 2025 is the largest year on record at $855, 7.2 times the $118 reported in 2019.
Across 40 payments — averaging $39.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$471
- Teva Pharmaceuticals USA, Inc.$213
- AstraZeneca$201
- Johnson & Johnson$118
- EMD Serono, Inc.$100
- UCB, Inc.$86
- plus $394 from 8 others
What the payments were for
- Food & beverage$1,53697%
- Education$483%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 11 | $471 |
| Teva Pharmaceuticals USA, Inc. | 2 | $213 |
| AstraZeneca | 5 | $201 |
| Johnson & Johnson | 1 | $118 |
| EMD Serono, Inc. | 2 | $100 |
| UCB, Inc. | 4 | $86 |
| Amgen | 1 | $76 |
| Catalyst Pharmaceuticals, Inc. | 3 | $71 |
| Bristol Myers Squibb | 3 | $69 |
| Tanabe Pharma America, Inc. | 3 | $58 |
| Genentech USA, Inc. | 2 | $48 |
| AbbVie | 1 | $34 |
| Acorda Therapeutics, Inc | 1 | $19 |
| Biogen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$213
- VYVGART$125
- XARELTO$118
- VYVGART HYTRULO$105
How this compares
$1,584 in reported general payments places this provider in the 60th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Riluzole | 30 | $6,044 |
| Pyridostigmine Bromide | 35 | $1,881 |
| Mycophenolate Mofetil | 13 | $1,546 |
| Gabapentin | 28 | $429 |
| Prednisone | 39 | $379 |
| Levetiracetam | 20 | $315 |
| Donepezil Hcl | 13 | $51 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boise
- Sergei KashirnyBoise$20K
- Anant WadhwaBoise$6K
- Jackie WhitesellBoise$2K
- Brittany LovascioBoise$2K
- Benjamin StewartBoise$2K
- Kelly BlockBoise$2K
- Thomas StrobelBoise$1K
- Lukas ClarkBoise$1K
- James WhitesideBoise$1K
- Daniel SimmonsBoise$729
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.